The Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy
Companion Diagnostics to Foster the Transformational Trend Towards Personalized Medicine
In 2009 the Biotechnology Industry was Dominated by the Top 10 Companies
The Prostate Cancer Therapeutics Market was driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy
The Cardiovascular, Oncology And Central Nervous System (CNS) Therapeutics Account For More Than 50% Of The Total Sales
The Global Diabetes Market is Lucrative Despite the Major Drugs in the Market being Associated with Heart Risks
Page 1 of 11